XOMA completed the acquisition of Kinnate Biopharma for $122m.

XOMA, a biotechnology royalty aggregator, completed the acquisition of Kinnate Biopharma, a clinical-stage precision oncology company, for $122m. Kinnate Biopharma is a clinical-stage precision oncology company founded with a mission to inspire hope in those battling cancer by expanding on the promise of targeted therapies.